Verastem Oncology to Present Data from RAMP 201 Trial at IGCS 2026

Verastem Oncology announced that new molecular profiling and tumor biomarker analyses from its Phase 2 RAMP 201 clinical trial of avutometinib plus defactinib in recurrent low-grade serous ovarian cancer will be presented at IGCS 2026.